Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

Ascletis reports strong Phase I efficacy and safety data for oral ASC50 in psoriasis.

What the company is saying

Ascletis Pharma Inc. (HKEX:1672) is highlighting positive results from a randomized, double-blind, placebo-controlled 28-day Phase I proof-of-concept trial of ASC50 in mild-to-moderate plaque psoriasis patients. The company emphasizes a 48.9% placebo-adjusted reduction in PASI score after 28 days of once-daily 200 mg dosing, with efficacy increasing to 60.7% at 6 days and 65.9% at 15 days post-treatment. Safety is a central theme, with all adverse events reported as mild and transient, no serious adverse events, no discontinuations, and no hepatic safety signals. The company frames ASC50 as a potential first-in-class and best-in-class oral small molecule IL-17A inhibitor, repeatedly underscoring the potential for once-weekly oral dosing based on a 6.5-day elimination half-life. Jinzi Jason Wu, Ph.D., Founder, Chairman, and CEO, is quoted to reinforce the narrative of ASC50 as a differentiated, needle-free alternative to injectable antibody therapies. The announcement positions ASC50 as a novel, in-house developed new chemical entity targeting a validated pathway for autoimmune and inflammatory diseases.

What the data suggests

The trial achieved a 48.9% placebo-adjusted reduction in PASI score after 28 days of daily 200 mg ASC50, with further improvements to 60.7% at 6 days and 65.9% at 15 days after the last dose. The reported steady-state elimination half-life of 6.5 days supports the plausibility of once-weekly dosing, though this regimen has not yet been tested. All adverse events were mild (Grade 1) and transient, with no serious adverse events, no discontinuations, and no elevations in ALT or AST, indicating a favorable safety profile. The company claims strong target engagement based on elevated plasma IL-17A levels, but does not provide quantitative data for this endpoint. The assertion of comparable efficacy to secukinumab is not substantiated by direct comparative or head-to-head data. No financial, commercial, or operational metrics are disclosed, and the results are limited to this early-stage, small-scale clinical setting. The evidence is robust for early efficacy and safety, but broader commercial and therapeutic claims remain unproven.

Analysis

The announcement presents robust Phase I clinical trial data for ASC50, with clear, specific efficacy and safety outcomes (e.g., 48.9% placebo-adjusted PASI reduction, no serious adverse events). These realised results are appropriately detailed and credible for an early-stage biotech update. However, the tone is inflated by repeated forward-looking statements about ASC50's 'potential' to be 'first-in-class' and 'best-in-class', and its possible role as a needle-free alternative to injectable therapies—claims that are not yet substantiated by head-to-head data or advanced clinical milestones. The comparison to secukinumab is not supported by direct evidence, and the assertion of strong target engagement lacks quantitative backing. No financial, operational, or commercialisation data is disclosed, and the path to market remains long-term, as only Phase I proof-of-concept data is available. The gap between narrative and evidence is moderate: the realised clinical results are solid, but the broader therapeutic and commercial claims are premature.

Risk flags

• ●The results are from a Phase I proof-of-concept study in mild-to-moderate plaque psoriasis, so efficacy and safety in larger, more diverse populations remain untested. Early-stage data often fail to translate into later-stage success.
• ●Forward-looking claims about once-weekly dosing and best-in-class status are not yet supported by direct evidence or comparative trials. The absence of head-to-head data with established therapies like secukinumab limits confidence in differentiation.
• ●No financial, operational, or commercial milestones are disclosed, leaving uncertainty about the company's ability to fund and execute subsequent clinical development, regulatory submissions, and eventual commercialization.

Bottom line

Ascletis delivers detailed Phase I data showing ASC50 achieves up to a 65.9% placebo-adjusted PASI reduction 15 days after the last dose, with a strong safety profile and no hepatic signals. The 6.5-day half-life suggests once-weekly dosing is feasible, but this has not yet been clinically tested. All claims of best-in-class potential and comparability to injectable therapies remain speculative without head-to-head or late-stage data. No financial or operational details are provided, so the announcement is not actionable from a near-term revenue or cash flow perspective. The most important takeaway is that ASC50 demonstrates promising early efficacy and safety, but investors must wait for larger trials and regulatory progress before assessing commercial potential. Watch for future updates on Phase II/III trial initiation, comparative data, and funding plans.

Announcement summary

(HKEX:1672) Ascletis Pharma Inc. announced positive results from a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical trial with ASC50 in mild-to-moderate plaque psoriasis patients in the U.S. The Phase I study (NCT07024602) evaluated the safety, efficacy, and pharmacokinetics of once-daily 200 mg ASC50 over 28 days. The trial achieved a placebo-adjusted reduction of 48.9% in psoriasis area and severity index (PASI) score after the 28-day treatment. The steady-state elimination half-life after 28-day treatment in patients was 6.5 days, supporting potential once-weekly oral dosing. The placebo-adjusted reduction in PASI score increased to 60.7% at 6 days and 65.9% at 15 days after the last dose (28th dose), further supporting the potential for once-weekly oral dosing. The 200 mg once-daily dosing demonstrated a comparable reduction in PASI score to published secukinumab data, though this was not a head-to-head study. Strong target engagement was observed after 28-day dosing, indicated by elevated plasma interleukin-17A (IL-17A) levels. The treatment was safe and well tolerated, with all adverse events being mild (Grade 1) and transient, and no serious adverse events reported. There were no discontinuations in the study. No alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations were observed, and no hepatic safety signal was detected. Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, stated that the efficacy, safety, and pharmacokinetic data support ASC50's potential as a first-in-class and best-in-class oral small molecule IL-17A inhibitor, offering a needle-free alternative to injectable antibody therapies. ASC50 is an in-house discovered and developed oral small molecule inhibitor targeting IL-17A, a validated target for multiple autoimmune and inflammatory diseases, including psoriasis. ASC50 is a new chemical entity (NCE) with a novel scaffold.

Disagree with this article?